Table 2.
Overview of survival endpoint data of our cohort compared with the two clinical trials a
| Our cohort | CHAARTED | STAMPEDE | ||
|---|---|---|---|---|
| Overall survival | All | 60.2 | 57.6 | 59.1 |
| High | 45.6 | 51.2 | 39.3 | |
| Low | MNR | 63.5 | 93.2 | |
| Time to CRPC | All | 26.2 | 19.4 | |
| High | 17.4 | 14.9 | ||
| Low | 33.3 | 31.0 | ||
| Time to clinical progression | All | 36.8 | 33.0 | |
| High | 26.1 | 27.3 | ||
| Low | 47.1 | 42.5 | ||
| Failure-free survival | All | 30.3 | 19.3 | |
| High | 19.6 | 14.0 | ||
| Low | 33.8 | 38.8 | ||
| Progression-free survival | All | 36.8 | 36.3 | |
| High | 26.1 | NA | ||
| Low | 47.1 | NA | ||
CHAARTED = Chemohormonal Therapy Versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer; CRPC = castration-resistant prostate cancer; MNR = median not reached; NA = not available; STAMPEDE = Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy.
a
Numbers are shown as median overall survival in months.